Categories
Change Password!
Reset Password!
Rabeprazole is the most preferred PPI for GERD patients on polypharmacy, driven by its minimal drug–drug interactions and favorable safety profile.
Tackling gastroesophageal reflux disease (GERD) in patients with multiple comorbidities and concurrent medications remains a clinical challenge, largely due to the risk of drug–drug interactions (DDIs). A recent survey of Indian healthcare professionals highlights growing confidence in rabeprazole as a safer and more effective option in such complex cases.
The cross-sectional survey gathered responses from healthcare professionals experienced in prescribing proton-pump inhibitors (PPIs). The questionnaire focused on prescribing patterns and challenges associated with polypharmacy in GERD management.
Key findings
The findings suggest that rabeprazole is widely perceived as a suitable PPI for GERD patients with comorbidities requiring multiple medications. Its reduced potential for drug interactions may yield a practical advantage, particularly in those on antiplatelet therapy or those at risk of adverse pharmacological interactions.
Journal of the Association of Physicians of India
Optimizing Proton-pump Inhibitor Therapy in Patients with Comorbidities Receiving Polypharmacy Treatment: Insights from Clinical Practice in India
Hemant T Juneja et al.
Comments (0)